{"id":"bupropion-wellbutrin-xl","safety":{"commonSideEffects":[{"rate":"15-20%","effect":"Insomnia"},{"rate":"10-15%","effect":"Dry mouth"},{"rate":"8-12%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"0.4%","effect":"Seizures"},{"rate":"5-10%","effect":"Agitation"},{"rate":"5-10%","effect":"Constipation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of norepinephrine and dopamine, bupropion increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their availability for receptor binding. This mechanism differs from selective serotonin reuptake inhibitors (SSRIs) and makes bupropion particularly useful for depression with anhedonia or fatigue. Wellbutrin XL is an extended-release formulation designed for once-daily dosing.","oneSentence":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:30.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"},{"name":"Smoking cessation (as Zyban®)"}]},"trialDetails":[{"nctId":"NCT06233799","phase":"PHASE3","title":"Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2024-07-01","conditions":"Methamphetamine-dependence, Methamphetamine Abuse","enrollment":360},{"nctId":"NCT07269873","phase":"PHASE1","title":"Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol","status":"NOT_YET_RECRUITING","sponsor":"BioCorRx Pharmaceuticals Inc","startDate":"2026-01-13","conditions":"Healthy Adult Male and Female Volunteers","enrollment":30},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT03078075","phase":"PHASE3","title":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Methamphetamine Use Disorder","enrollment":403},{"nctId":"NCT01982643","phase":"PHASE1, PHASE2","title":"Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"Walter Ling","startDate":"2013-11","conditions":"Methamphetamine Use Disorder","enrollment":49},{"nctId":"NCT03001440","phase":"","title":"A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-07","conditions":"Depressive Disorder, Major","enrollment":1},{"nctId":"NCT01046214","phase":"PHASE1","title":"Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions","status":"TERMINATED","sponsor":"Teva Pharmaceuticals USA","startDate":"2010-01","conditions":"Depressive Disorder","enrollment":8},{"nctId":"NCT01477931","phase":"PHASE4","title":"Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features","status":"COMPLETED","sponsor":"Chi-Un Pae","startDate":"2010-11","conditions":"Depressive Disorder, Major","enrollment":50},{"nctId":"NCT00863941","phase":"PHASE1","title":"A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-06","conditions":"Healthy","enrollment":28},{"nctId":"NCT00865462","phase":"PHASE1","title":"A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-07","conditions":"Healthy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arm: Experimental - Active Medication Combination (AMC)"],"phase":"phase_3","status":"active","brandName":"Bupropion: Wellbutrin XL®","genericName":"Bupropion: Wellbutrin XL®","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as Zyban®).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}